Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) (ProGen)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03328091 |
Recruitment Status :
Completed
First Posted : November 1, 2017
Last Update Posted : January 18, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
Information provided by (Responsible Party):
Huma Rana, MD, Dana-Farber Cancer Institute
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | October 25, 2017 | ||||
First Posted Date ICMJE | November 1, 2017 | ||||
Last Update Posted Date | January 18, 2024 | ||||
Actual Study Start Date ICMJE | November 21, 2017 | ||||
Actual Primary Completion Date | February 13, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Prevalence of germline mutations in males with prostate cancer [ Time Frame: 2 years ] The proportion of participants who test positive for pathogenic or likely pathogenic variants
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) | ||||
Official Title ICMJE | Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) | ||||
Brief Summary | This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. | ||||
Detailed Description | Participants will be randomized to either pre-test video education and post-test genetic counseling or in-person pre-test genetic counseling. Outcomes evaluated are: prevalence of germline mutations, uptake of genetic testing, satisfaction with testing, knowledge of multi-gene panels, distress, result disclosure to relatives, and the impact on personal or family medical care. Through this study, the investigators will learn about the inherited causes of prostate cancer, and how and when genetic testing should be offered to this population. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Supportive Care |
||||
Condition ICMJE | Prostate Cancer | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, Siegmund S, Tewari AK, Nowak JA, Lindeman NI, Rana HQ, Choudhury AD, Pomerantz MM, Freedman ML, Van Allen EM, Taplin ME. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022 Aug;6:e2200329. doi: 10.1200/PO.22.00329. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
662 | ||||
Original Estimated Enrollment ICMJE |
450 | ||||
Actual Study Completion Date ICMJE | February 13, 2020 | ||||
Actual Primary Completion Date | February 13, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03328091 | ||||
Other Study ID Numbers ICMJE | 17-409 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Huma Rana, MD, Dana-Farber Cancer Institute | ||||
Original Responsible Party | Huma Rana, Dana-Farber Cancer Institute, Principal Investigator | ||||
Current Study Sponsor ICMJE | Dana-Farber Cancer Institute | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE |
|
||||
PRS Account | Dana-Farber Cancer Institute | ||||
Verification Date | January 2024 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |